|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Fulcrum Therapeutics, Inc. (FULC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
63,029,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases. Co. has developed a proprietary product engine, FulcrumSeek, that it employs to systematically identify and validate cellular drug targets. Co.' products include: losmapimod, a small molecule that it is developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive and disabling disorder characterized by muscle degeneration and fat infiltration; and FTX-6058, an investigational oral fetal hemoglobin, inducer that is in development for sickle cell disease and select other hemoglobinopathies, including ss-thalassemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
43,360 |
43,360 |
43,360 |
4,472,361 |
| Total Buy Value |
$492,028 |
$492,028 |
$492,028 |
$39,173,214 |
| Total People Bought |
1 |
1 |
1 |
2 |
| Total Buy Transactions |
1 |
1 |
1 |
7 |
| Total Shares Sold |
5,120 |
5,120 |
5,120 |
150,153 |
| Total Sell Value |
$59,050 |
$59,050 |
$59,050 |
$1,271,940 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
2 |
2 |
2 |
8 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sanofi-Aventis |
10% Owner |
– – • |
2019-07-22 |
4 |
B |
$16.00 |
$1,500,000 |
I/I |
93,750 |
558,035 |
1.5 |
- |
|
| Sanofi-Aventis |
10% Owner |
– – • |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
464,285 |
464,285 |
|
- |
|
| Maris William J |
10% Owner |
– – • |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
464,285 |
464,285 |
|
- |
|
| Casdin Eli |
10% Owner |
– – • |
2019-07-22 |
4 |
B |
$14.50 |
$2,217,495 |
I/I |
140,000 |
604,285 |
1.5 |
- |
|
| Casdin Eli |
10% Owner |
– – • |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
464,285 |
464,285 |
|
- |
|
| 6 Dimensions Capital, L.p. |
10% Owner |
– – • |
2019-07-22 |
4 |
B |
$16.00 |
$1,900,000 |
D/D |
118,750 |
559,821 |
2.45 |
- |
|
| 6 Dimensions Capital, L.p. |
10% Owner |
– – • |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
441,071 |
441,071 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2019-07-22 |
4 |
B |
$16.00 |
$1,300,000 |
D/D |
81,250 |
5,962,202 |
2.45 |
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
5,595,238 |
5,880,952 |
|
- |
|
| Trv Gp Iv, Llc |
10% Owner |
– – • |
2019-07-22 |
4 |
B |
$16.00 |
$1,300,000 |
D/D |
81,250 |
2,343,154 |
2.45 |
- |
|
| Trv Gp Iv, Llc |
10% Owner |
– – • |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,261,904 |
2,261,904 |
|
- |
|
| Levin Mark J |
Director |
– • • |
2019-07-22 |
4 |
B |
$16.00 |
$1,300,000 |
I/I |
81,250 |
5,962,202 |
2.25 |
- |
|
| Levin Mark J |
Director |
– • • |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
5,595,238 |
5,880,952 |
|
- |
|
| Cadavid Diego |
See RemarksOfficer |
• – – |
2019-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
71,071 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2019-07-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
285,714 |
|
- |
|
| Levin Mark J |
Director |
– • • |
2019-07-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
285,714 |
|
- |
|
| Ezekowitz Alan |
Director |
– • – |
2019-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
28,927 |
|
- |
|
| Thomson Peter G. |
See RemarksOfficer |
• – – |
2019-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
38,571 |
|
- |
|
| Wallace Owen B. |
Chief Scientific OfficerOffice |
• – – |
2019-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
127,088 |
|
- |
|
| Gould Robert J |
See RemarksOfficer |
• • • |
2019-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
557,345 |
|
- |
|
| Geraghty James A |
Director |
– • – |
2019-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
80,714 |
|
- |
|
| Collins James J. |
Director |
– • – |
2019-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
23,571 |
|
- |
|
122 Records found
|
|
Page 5 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
